Specification
| Target | LAG3 |
| Clone | Relatlimab |
| Isotype | Human IgG4(S228P)-Kappa |
| Expression System | CHO |
| Purification | Protein A |
| Recommended Isotope Control | Anti-HEL Human IgG4 (S228P)-Kappa Isotype control |
| Recommended Dilution Buffer | PBS, pH 7.35 |
| Formulation | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Storage | This antibody can be storaged at 2°C to 8 °C for 2 weeks under sterile conditions;-20°C for 3 months under sterile conditions;-70°C for 36 months under sterile conditions.Avoid repeated freeze-thaw. |
| Disclaim | For Research Use Only |
Background
| Background | Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).3,4 It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,1 and has garnered interest in the treatment of a variety of cancers, including leukemia2 and melanoma.6 As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like nivolumab or CTLA-4 inhibitors like ipilimumab - to enhance their efficacy. |
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |